Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation

Ophthalmology

Volumn 105, Issue 1, 1998, Pages 88-93

  Rosenberg, Lisa F ^a,b   Krupin, Theodore ^a   Tang, Li Qi ^a   Hong, Pauline H ^a   Ruderman, Jon M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; EYE DROPS; FLUORESCEIN; FLURESS;

ADULT; AQUEOUS HUMOR FLOW; AQUEOUS HUMOR FORMATION; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FLUOROPHOTOMETRY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; OPEN ANGLE GLAUCOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET; TONOMETRY; TOPICAL DRUG ADMINISTRATION;

EID: 0031891081     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(98)91421-X     Document Type: Article

References (13)

1. Lippa EA, Schuman JS, Higginbotham EJ, et al. MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991;98:308-13.
2. Lippa EA, Carlson LE, Ehinger B, et al. Dose response and duration of action of dorzolamide a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992;110:495-9.
3. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993; 111:1343-50.
4. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide, (Trusopt), timolol, and betaxalol. Arch Ophthalmol 1995;113:1009-16.
5. Kitazawa Y, Yamamoto T, Azuma I. Effect of MK-507 switch-over from oral carbonic anhydrase inhibitors in primary open-angle glaucoma. Folia Ophthalmol Jpn 1994;45:914-20.
6. Yablonski ME, Cook DJ, Gray J. A fluorophotometric study of the effect of argon laser trabeculoplasty on aqueous humor dynamics. Am J Ophthalmol 1985;99:579-82.
7. Biollaz J, Munafo A, Buclin T, et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol 1995;47:455-60.
8. Strahlman ER, Vogel R, Tipping R, et al. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 1996;103:1283-93.
9. Yamazaki Y, Miyamoto S, Sawa M. Effect of MK-507 on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol 1994;38:92-6.
10. Brechue WF, Maren TH. A comparison between the effect of topical and systemic carbonic-anhydrase inhibitors on aqueous-humor secretion. Exp Eye Res 1993;57:67-78.
11. Krupin T, Oestrich CJ, Bass J, et al. Acidosis, alkalosis, and aqueous humor dynamics in rabbits. Invest Ophthalmol Vis Sci 1977;16:997-1001.
12. Maus TL, Larsson LI, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997;115:45-9.
13. Brubaker RF. Flow of aqueous humor in humans. The Friedenwaid Lecture. Invest Ophthalmol Vis Sci 1991; 32:3145-66.